# Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma

> **NCT02502370** · PHASE3 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 100 (estimated)

## Conditions studied

- Small Bowel Adenocarcinoma
- Adjuvant Chemotherapy for SBA

## Interventions

- **DRUG:** observation alone
- **DRUG:** LV5FU2
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT02502370
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** 2023-09
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2015-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02502370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02502370, "Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02502370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*